|
|
Volumn 370, Issue 9592, 2007, Pages 1031-1032
|
|
Effects of quadrivalent human papillomavirus vaccination
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PLACEBO;
WART VIRUS VACCINE;
HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;
PAPILLOMA VIRUS VACCINE;
UNCLASSIFIED DRUG;
CANCER STAGING;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
HUMAN;
LETTER;
PRIORITY JOURNAL;
UTERINE CERVIX CARCINOMA IN SITU;
VACCINATION;
VIRUS TYPING;
WART VIRUS;
COST BENEFIT ANALYSIS;
DEVELOPED COUNTRY;
DEVELOPING COUNTRY;
FEMALE;
NOTE;
PATHOLOGY;
PREVALENCE;
CANCER CHEMOTHERAPY;
DRUG EFFICACY;
MORBIDITY;
PUBLIC HEALTH PROBLEM;
PUBLIC HEALTH SERVICE;
UTERINE CERVIX CANCER;
ADENOCARCINOMA;
CLASSIFICATION;
MULTICENTER STUDY;
TREATMENT OUTCOME;
CERVICAL INTRAEPITHELIAL NEOPLASIA;
COST-BENEFIT ANALYSIS;
DEVELOPED COUNTRIES;
DEVELOPING COUNTRIES;
FEMALE;
HUMANS;
PAPILLOMAVIRUS VACCINES;
PREVALENCE;
ADENOCARCINOMA;
MULTICENTER STUDIES;
TREATMENT OUTCOME;
|
|
EID: 34548665943
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(07)61471-8 Document Type: Letter |
|
Times cited : (6)
|
|
References (5)
|
